Argenx discontinues phase 3 Unity study of efgartigimod SC in Sjögren's disease
ARGX•Argenx discontinued its phase 3 Unity study of efgartigimod SC in Sjögren's disease after an independent monitoring committee recommended stopping for futility; the study could not meet its primary endpoint, and no new safety signals were identified.
1. Study stopped for futility
Argenx discontinued the phase 3 Unity study of efgartigimod SC in Sjögren's disease following an independent data monitoring committee recommendation to stop for futility. The committee concluded the study could not meet its primary endpoint; no new safety signals were identified.
